Product Information
TOUJEO MAX SOLOSTR 300 UNIT/ML is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $91.3004 per ML under NDC 00024587102. Its NADAC has been published 420 times since Sep 19, 2018.
Strength
300 U/mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00024587102
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLARGINEApproval Type
Biologic (BLA)
FDA Application
BLA206538On Market Since
2/15/2015
Pharmacological Classes
Price Statistics
The NADAC for TOUJEO MAX SOLOSTR 300 UNIT/ML has been published 420 times since Sep 19, 2018, and over the history we have for it it has risen 13.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $91.3004 per ML |
|---|---|
| All-time high | $91.4382 (Sep 11, 2024) |
| All-time low | $80.3938 (Sep 19, 2018) |
| 52-week high | $91.3545 |
| 52-week low | $91.2360 |
| Median price | $83.9303 |
| Average price | $86.2769 |
| Largest weekly change | +5.0% (Jan 11, 2023) |
| Weeks tracked | 420 |
| Tracking since | Sep 19, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 70% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin glargine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOUJEO MAX SOLOSTR 300 UNIT/ML?
The current National Average Drug Acquisition Cost (NADAC) for TOUJEO MAX SOLOSTR 300 UNIT/ML, manufactured by Sanofi-Aventis U.S. LLC, is $91.3004 per ML (NDC 00024587102), effective Sep 30, 2026.
How has the price of TOUJEO MAX SOLOSTR 300 UNIT/ML changed over time?
Over the history we have for it, the NADAC for TOUJEO MAX SOLOSTR 300 UNIT/ML has risen 13.6%. It has been tracked across 420 weekly CMS publications since Sep 19, 2018.
What are the highest and lowest recorded NADAC prices for TOUJEO MAX SOLOSTR 300 UNIT/ML?
Since Sep 19, 2018, the NADAC for TOUJEO MAX SOLOSTR 300 UNIT/ML has ranged from a low of $80.3938 (Sep 19, 2018) to a high of $91.4382 (Sep 11, 2024), with a median of $83.9303 per ML.
Are there cheaper alternatives to TOUJEO MAX SOLOSTR 300 UNIT/ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, INSULIN GLARGINE SOLOSTAR U300, is $27.0054 per ML — about 70% below TOUJEO MAX SOLOSTR 300 UNIT/ML.
Who manufactures TOUJEO MAX SOLOSTR 300 UNIT/ML?
TOUJEO MAX SOLOSTR 300 UNIT/ML (NDC 00024587102) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.